Experience

IRCCS - Institut de Recherche Clinique sur les Cancers et le Sang

• France
• Research Services
• 1 - 100 Employee

• Clinical Study Coordinator - Hematology

  • Feb 2019 - Present

  - Specialised in lymphoma and myeloma pathologies. - Management of 20 clinical trials phase I (including FIH), II and III, from the site initiation visit to the site close-out visit, which include : ->Standard chemotherapy, alone or combine with others drugs ->Immunotherapy : mono & bispecific antibodies ->CAR-T cells therapy - Specialised in lymphoma and myeloma pathologies. - Management of 20 clinical trials phase I (including FIH), II and III, from the site initiation visit to the site close-out visit, which include : ->Standard chemotherapy, alone or combine with others drugs ->Immunotherapy : mono & bispecific antibodies ->CAR-T cells therapy



HP2 LABORATOIRE

• France
• Research Services
• 1 - 100 Employee

• Research project assistant - Cardiometablic physiology

  • Oct 2017 - Jun 2018

  Inserm - HP2 Laboratory Cardiometabolic alterations induced by chronic intermittent hypoxia (CIH), on lean or obese mice : role of the cardiac insulin signalisation. Inserm - HP2 Laboratory Cardiometabolic alterations induced by chronic intermittent hypoxia (CIH), on lean or obese mice : role of the cardiac insulin signalisation.



INSERM

• France
• Research Services
• 700 & Above Employee

• Research project assistant - Nutritional and metabolic physiology

  • Jan 2017 - Feb 2017

  Inserm U1213 : Team "Nutrition, diabetes and brain" Study of the impact of renal and intestinal invalidation of the G6pc gene on carbohydrate metabolism during fasting in mice. Inserm U1213 : Team "Nutrition, diabetes and brain" Study of the impact of renal and intestinal invalidation of the G6pc gene on carbohydrate metabolism during fasting in mice.



INSERM

• France
• Research Services
• 700 & Above Employee

• Research project assistant - Oncology

  • Apr 2015 - May 2015

  UMRS 935 - Malignant stem cell models and therapeutics Team 3 - Chronotherapy of cancer and optimisation of liver function Study of the effect of two anticancer agents (everolimus and irinotecan) on cultured mouse hepatocarnicomas: inactivation of genes involved in the regulation of the circadian clock in order to study their impact on the effectiveness of the two targeted anticancer agents. UMRS 935 - Malignant stem cell models and therapeutics Team 3 - Chronotherapy of cancer and optimisation of liver function Study of the effect of two anticancer agents (everolimus and irinotecan) on cultured mouse hepatocarnicomas: inactivation of genes involved in the regulation of the circadian clock in order to study their impact on the effectiveness of the two targeted anticancer agents.